Evidence map›Paper›PMID 25027317›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2014

Intranasal administration as a route for drug delivery to the brain: evidence for a unique pathway for albumin.

Joseph A Falcone, Therese S Salameh, Xiang Yi, Benjamin J Cordy, William G Mortell, Alexander V Kabanov, William A Banks

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 88 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Intranasal drug delivery for treatment of Alzheimer's disease.Drug delivery and translational research · 2021
    Review
  19. Article
  20. Characterization of focused ultrasound-mediated brainstem delivery of intranasally administered agents.Journal of controlled release : official journal of the Controlled Release Society · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Joseph A FalconeDivision of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine (J.A.F., T.S.S., W.A.B.) and Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington (J.A.F., T.S.S., X.Y., B.J.C., W.G.M., W.A.B.); Center for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (X.Y., A.V.K.); and Faculty of Chemistry, M.V. Lomonosov Moscow State University, Moscow, Russia (A.V.K.).
Therese S SalamehDivision of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine (J.A.F., T.S.S., W.A.B.) and Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington (J.A.F., T.S.S., X.Y., B.J.C., W.G.M., W.A.B.); Center for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (X.Y., A.V.K.); and Faculty of Chemistry, M.V. Lomonosov Moscow State University, Moscow, Russia (A.V.K.).
Xiang YiDivision of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine (J.A.F., T.S.S., W.A.B.) and Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington (J.A.F., T.S.S., X.Y., B.J.C., W.G.M., W.A.B.); Center for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (X.Y., A.V.K.); and Faculty of Chemistry, M.V. Lomonosov Moscow State University, Moscow, Russia (A.V.K.).
Benjamin J CordyDivision of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine (J.A.F., T.S.S., W.A.B.) and Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington (J.A.F., T.S.S., X.Y., B.J.C., W.G.M., W.A.B.); Center for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (X.Y., A.V.K.); and Faculty of Chemistry, M.V. Lomonosov Moscow State University, Moscow, Russia (A.V.K.).
William G MortellDivision of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine (J.A.F., T.S.S., W.A.B.) and Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington (J.A.F., T.S.S., X.Y., B.J.C., W.G.M., W.A.B.); Center for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (X.Y., A.V.K.); and Faculty of Chemistry, M.V. Lomonosov Moscow State University, Moscow, Russia (A.V.K.).
Alexander V KabanovDivision of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine (J.A.F., T.S.S., W.A.B.) and Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington (J.A.F., T.S.S., X.Y., B.J.C., W.G.M., W.A.B.); Center for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (X.Y., A.V.K.); and Faculty of Chemistry, M.V. Lomonosov Moscow State University, Moscow, Russia (A.V.K.).
William A BanksDivision of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine (J.A.F., T.S.S., W.A.B.) and Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington (J.A.F., T.S.S., X.Y., B.J.C., W.G.M., W.A.B.); Center for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (X.Y., A.V.K.); and Faculty of Chemistry, M.V. Lomonosov Moscow State University, Moscow, Russia (A.V.K.) wabanks1@uw.edu.
University of North Carolina at Chapel Hill · USUniversity of Washington · USGeriatric Research Education and Clinical Center · USLomonosov Moscow State University · RUVA Puget Sound Health Care System · US

Funding

NEUROBEHAVIOR, NEUROENDOCRINOLOGY, AND GENETICS OF ADT32AG000258 · NIA · UNIVERSITY OF WASHINGTON · PI MONTINE, THOMAS J · 1999 to 2013
$4.7M
NIA NIH HHS T32 AG000258NIA NIH HHS T32-AG000258NINDS NIH HHS R01-NS051134
6 · The paper itself

Abstract

A variety of compounds will distribute into the brain when placed at the cribriform plate by intranasal (i.n.) administration. In this study, we investigated the ability of albumin, a protein that can act as a drug carrier but is excluded from brain by the blood-brain barrier, to distribute into the brain after i.n. administration. We labeled bovine serum albumin with [(125)I] ([(125)I]Alb) and studied its uptake into 11 brain regions and its entry into the blood from 5 minutes to 6 hours after i.n. administration. [(125)I]Alb was present throughout the brain at 5 minutes. Several regions showed distinct peaks in uptake that ranged from 5 minutes (parietal cortex) to 60 minutes (midbrain). About 2-4% of the i.n. [(125)I]Alb entered the bloodstream. The highest levels occurred in the olfactory bulb and striatum. Distribution was dose-dependent, with less taken up by whole brain, cortex, and blood at the higher dose of albumin. Uptake was selectively increased into the olfactory bulb and cortex by the fluid-phase stimulator PMA (phorbol 12-myristate 13-acetate), but inhibitors to receptor-mediated transcytosis, caveolae, and phosphoinositide 3-kinase were without effect. Albumin altered the distribution of radioactive leptin given by i.n. administration, decreasing uptake into the blood and by the cerebellum and increasing uptake by the hypothalamus. We conclude that [(125)I]Alb administered i.n. reaches all parts of the brain through a dose-dependent mechanism that may involve fluid-phase transcytosis and, as illustrated by leptin, can affect the delivery of other substances to the brain after their i.n. administration.

Indexed as

Administration, IntranasalAnimalsBrainLeptinMaleMicePharmaceutical VehiclesSerum Albumin, BovineTetradecanoylphorbol AcetateTissue DistributionLeptinPharmaceutical VehiclesSerum Albumin, BovineTetradecanoylphorbol Acetate

Identifiers

PMID25027317
PMCPMC4165023
OpenAlexW2171125861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.